Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

sterling-knight pharmaceuticals, llc - foraxa rx skin emulsion is indicated as a prescription topical skin care emulsion for the management of painful wounds. foraxa rx skin emulsion helps maintain a moist wound and skin environment, which is beneficial to the healing process. directions: apply a small amount of foraxa rx emulsion in sufficient quantity to cover the affected skin area to be protected, and allow to dry. reapply up to 4 times per day (or as needed). apply a small amount of foraxa rx emulsion in sufficient quantity to cover the affected skin area to be protected, and allow to dry. reapply up to 4 times per day (or as needed).

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

sterling-knight pharmaceuticals, llc - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals ( see warnings; gastrointestinal bleeding, ulceration, and perforation). diclofenac is indicated: - for relief of the signs and symptoms of osteoarthritis - for relief of the signs and symptoms of rheumatoid arthritis - for acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis diclofenac sodium delayed-release tablets are contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product ( see warnings; anaphylactic reactions, serious skin reactions). - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaid

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

sterling-knight pharmaceuticals, llc - benzonatate (unii: 5p4dhs6enr) (benzonatate - unii:5p4dhs6enr) - benzonatate usp is indicated for the symptomatic relief of cough. hypersensitivity to benzonatate or related compounds. safety and effectiveness in children below the age of 10 have not been established. accidental ingestion resulting in death has been reported in children below age 10. keep out of reach of children.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

sterling-knight pharmaceuticals, llc - metaxalone (unii: 1nma9j598y) (metaxalone - unii:1nma9j598y) - metaxalone tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions. the mode of action of this drug has not been clearly identified, but may be related to its sedative properties. metaxalone does not directly relax tense skeletal muscles in man. known hypersensitivity to any components of this product. known tendency to drug induced, hemolytic, or other anemias. significantly impaired renal or hepatic function.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

sterling-knight pharmaceuticals,llc - lidocaine (unii: 98pi200987) (lidocaine - unii:98pi200987), prilocaine (unii: 046o35d44r) (prilocaine - unii:046o35d44r) - lidocaine 25 mg in 1 g - lidocaine and prilocaine cream (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on: - normal intact skin for local analgesia. - genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. lidocaine and prilocaine cream is not recommended in any clinical situation when penetration or migration beyond the tympanic membrane into the middle ear is possible because of the ototoxic effects observed in animal studies (see warnings). lidocaine and prilocaine cream (lidocaine 2.5% and prilocaine 2.5%) is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type or to any other component of the product.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

sterling-knight pharmaceuticals,llc - lidocaine (unii: 98pi200987) (lidocaine - unii:98pi200987), prilocaine (unii: 046o35d44r) (prilocaine - unii:046o35d44r) - lidocaine 25 mg in 1 g - lidocaine and prilocaine cream (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on: - normal intact skin for local analgesia. - genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. lidocaine and prilocaine cream is not recommended in any clinical situation when penetration or migration beyond the tympanic membrane into the middle ear is possible because of the ototoxic effects observed in animal studies (see warnings). lidocaine and prilocaine cream (lidocaine 2.5% and prilocaine 2.5%) is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type or to any other component of the product.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

sterling-knight pharmaceuticals,llc - lidocaine (unii: 98pi200987) (lidocaine - unii:98pi200987), prilocaine (unii: 046o35d44r) (prilocaine - unii:046o35d44r) - lidocaine 25 mg in 1 g - lidocaine and prilocaine cream (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on: - normal intact skin for local analgesia. - genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. lidocaine and prilocaine cream is not recommended in any clinical situation when penetration or migration beyond the tympanic membrane into the middle ear is possible because of the ototoxic effects observed in animal studies (see warnings). lidocaine and prilocaine cream (lidocaine 2.5% and prilocaine 2.5%) is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type or to any other component of the product.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

sterling knight pharmaceuticals,llc - cyclobenzaprine hydrochloride (unii: 0ve05jys2p) (cyclobenzaprine - unii:69o5wqq5ti) - cyclobenzaprine hydrochloride 5 mg - cyclobenzaprine hydrochloride tablets, usp are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion and restriction in activities of daily living. cyclobenzaprine hydrochloride tablets, usp should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. cyclobenzaprine hydrochloride tablets, usp have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy. hypersensitivity to any component of this product. concomitant use of monoamine oxidase (mao) inhi

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

sterling knight pharmaceuticals llc - fenoprofen calcium (unii: 0x2cw1qabj) (fenoprofen - unii:ra33eac7ky) - fenoprofen 200 mg - fenortho is indicated for: - relief of mild to moderate pain in adults. - relief of the signs and symptoms of rheumatoid arthrites. - relief of the signs and symptoms of osteoarthritis. fenortho is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to fenoprofen or any components of the drug product [ see warnings and precautions ( 5.7, 5.9) ] - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [ see warnings and precautions ( 5.7, 5.8) ] - in the setting of coronary artery bypass graft (cabg) surgery [ see warnings and precautions ( 5.1) ] risk summary use of nsaids, including fenortho, during the thir

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

sterling-knight pharmaceuticals, llc - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - phenobarbital 97.2 mg - a. sedative b. anticonvulsant – for the treatment of generalized and partial seizures. phenobarbital is contraindicated in patients who are hypersensitive to barbiturates, in patients with a history of manifest or latent porphyria, and in patients with marked impairment of liver function or respiratory disease in which dyspnea or obstruction is evident. controlled substance – phenobarbital is a schedule iv drug. dependence – barbiturates may be habit forming. tolerance, psychological dependence, and physical dependence may occur, especially following prolonged use of high doses of barbiturates. daily administration in excess of 400 mg of pentobarbital or secobarbital for approximately 90 days is likely to produce some degree of physical dependence. a dosage of 600 to 800 mg taken for at least 35 days is sufficient to produce withdrawal seizures. the average daily dose for the barbiturate addict is usually about 1.5 g. as tolerance to barbiturates develops, the amount needed to maintain the sam